Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CNS

This article was originally published in The Tan Sheet

Executive Summary

Breathe Right line extension expected to debut in March 2002, and CNS will enter a new product category later next year, company says during July 19 analysts call on Q2 results. Overall first-half sales reached $42.6 mil. compared to $27.9 mil. a year ago, while Q2 sales grew 16.5% to $15.5 mil., slightly outpacing earlier projections (1"The Tan Sheet" July 2, p. 8). "Disappointing" Fiberchoice sales of $5 mil. in first half causing CNS to reduce second-half marketing expenditures by about $7 mil. compared to first six months, company says

You may also be interested in...



CNS Restructuring Plan Focused On Bolstering Breathe Right Sales

CNS recorded a $1.2 mil. charge against earnings in the second quarter as part of a restructuring plan aimed at strengthening its core Breathe Right nasal strip business and returning the firm to sustainable profitability.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Topics

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel